TABLE 2.
Living/Uncured Patients (N = 5138)
| Variables | Response | Row Total (N = 5138) (Row %) |
GT1 [n (%)]
|
GT2 [n (%)]
|
GT3 (N = 461) (9.0%) |
GT4 (N = 81) (1.6%) |
GT6 (N = 12) (0.2%) |
P | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All (N = 4056) (78.9%) |
1A (N =2470) (48.1%) |
1B (N=1236) (24.1%) |
Other (N = 350) (6.9%) |
All (N = 528) (10.3%) |
2A (N=40) (0.8%) |
2B (N=338) (6.6%) |
Other (N=150) (2.9%) |
|||||||
| A: Distribution of HCV GT/ST across patient characteristics (row percentages shown for categories) | ||||||||||||||
| Site | GHS | 1257 | 962 (77) | 621 (49) | 170 (14) | 171 (14) | 150 (12) | 7 (1) | 105 (8) | 38 (3) | 118 (9) | 27 (2) | 0 (0) | |
| HFHS | 2013 | 1749 (87) | 990 (49) | 690 (34) | 69 (3) | 94 (5) | 25 (1) | 55 (3) | 14 (1) | 138 (7) | 32 (2) | 1 (0) | ||
| KPHI | 521 | 392 (75) | 263 (50) | 104 (20) | 25 (5) | 65 (12) | 6 (1) | 41 (8) | 18 (3) | 60 (12) | 2 (0) | 2 (0) | ||
| KPNW | 1346 | 953 (71) | 596 (44) | 272 (20) | 85 (6) | 219 (16) | 2 (0) | 137 (10) | 80 (6) | 145 (11) | 20 (1) | 9 (1) | ||
| Sex | Male | 3058 | 2431 (79) | 1475 (48) | 750 (25) | 206 (7) | 300 (10) | 15 (0) | 198 (6) | 87 (3) | 284 (9) | 36 (1) | 7 (0) | |
| Female | 2079 | 1625 (78) | 995 (48) | 486 (23) | 144 (7) | 228 (11) | 25 (1) | 140 (7) | 63 (3) | 177 (9) | 45 (2) | 5 (0) | ||
| Race | Asian/Other | 549 | 393 (72) | 238 (43) | 126 (23) | 29 (5) | 70 (13) | 5 (1) | 36 (7) | 29 (5) | 58 (11) | 16 (3) | 12 (2) | |
| Black | 1322 | 1253 (95) | 666 (50) | 526 (40) | 61 (5) | 48 (4) | 15 (1) | 23 (2) | 10 (1) | 15 (1) | 7 (1) | 0 (0) | ||
| White | 3266 | 2410 (74) | 1566 (48) | 584 (18) | 260 (8) | 410 (13) | 20 (1) | 279 (9) | 111 (3) | 388 (12) | 58 (2) | 0 (0) | ||
| Birth year | < 1946 | 453 | 368 (81) | 162 (36) | 182 (40) | 24 (5) | 63 (14) | 10 (2) | 41 (9) | 12 (3) | 11 (2) | 8 (2) | 3 (1) | |
| 1946≤1955 | 2226 | 1862 (84) | 1073 (48) | 651 (29) | 138 (6) | 195 (9) | 14 (1) | 121 (5) | 60 (3) | 136 (6) | 30 (1) | 3 (0) | ||
| 1956≤1965 | 1590 | 1189 (75) | 771 (48) | 295 (19) | 123 (8) | 180 (11) | 10 (1) | 114 (7) | 56 (4) | 198 (12) | 19 (1) | 4 (0) | ||
| 1966≤1975 | 411 | 301 (73) | 196 (48) | 70 (17) | 35 (9) | 51 (12) | 5 (1) | 32 (8) | 14 (3) | 52 (13) | 6 (1) | 2 (0) | ||
| ≥1976 | 457 | 336 (74) | 268 (59) | 38 (8) | 30 (7) | 39 (9) | 1 (0) | 30 (7) | 8 (2) | 64 (14) | 18 (4) | 0 (0) | ||
| Variables | Response | Living/uncured (N = 5138) | GT2 [n (%)]
|
GT1 [n (%)]
|
GT3 (N = 461) | GT4 (N = 81) | GT6 (N = 12) | P-value (for “All” GT only) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All (N = 4056) | 1A (N = 2470) | 1B (N = 1236) | Other (N = 350) | All (N = 528) | 2A (N = 40) | 2B (N = 338) | Other (N = 150) | |||||||
| B: Distribution of clinical characteristics by GT/ST (column percentages shown by category for each GT/ST) | ||||||||||||||
| Treatment status | Treatment failure | 1721 (33) | 1412 (35) | 855 (35) | 422 (34) | 135 (39) | 132 (25) | 11 (28) | 81 (24) | 40 (27) | 146 (32) | 30 (37) | 1 (8) | < 0.0001 |
| Untreated | 3417 (66) | 2644 (65) | 1615 (65) | 814 (66) | 215 (61) | 396 (75) | 29 (73) | 257 (76) | 110 (73) | 315 (68) | 51 (63) | 11 (92) | ||
| ALT available (n = 3715) | <LLN and/or Normal | 2101 (6) | 1694 (57) | 1008 (56) | 565 (62) | 121 (49) | 233 (61) | 21 (78) | 150 (60) | 62 (59) | 137 (44) | 31 (54) | 7 (58) | < 0.0001 |
| ULN≤2xULN | 1092 (3) | 883 (30) | 557 (31) | 239 (26) | 87 (35) | 90 (23) | 3 (11) | 61 (24) | 26 (25) | 97 (31) | 19 (33) | 3 (25) | ||
| > 2xULN | 522 (1) | 378 (13) | 235 (13) | 104 (11) | 39 (16) | 60 (16) | 3 (11) | 40 (16) | 17 (16) | 76 (25) | 7 (12) | 1 (8) | ||
| FIB4 available (n = 3173) | ≤1.21 | 772 (24) | 596 (24) | 405 (26) | 136 (18) | 55 (25) | 87 (27) | 11 (50) | 59 (29) | 17 (18) | 72 (26) | 14 (29) | 3 (25) | < 0.0001 |
| 1.21≤5.88 | 1961 (62) | 1584 (63) | 942 (61) | 502 (67) | 140 (64) | 206 (64) | 10 (45) | 125 (61) | 71 (76) | 147 (54) | 21 (43) | 3 (25) | ||
| > 5.88 | 440 (14) | 340 (13) | 207 (13) | 109 (15) | 24 (11) | 29 (9) | 1 (5) | 22 (11) | 6 (6) | 54 (20) | 14 (29) | 3 (25) | ||
| Decompensated cirrhosis | Yes | 134 (3) | 106 (3) | 53 (2) | 49 (4) | 4 (1) | 11 (2) | 2 (5) | 8 (2) | 1 (1) | 16 (3) | 1 (1) | 0 (0) | 0.288 |
| No | 5004 (97) | 3950 (97) | 2417 (98) | 1187 (96) | 346 (99) | 517 (98) | 38 (95) | 330 (98) | 149 (99) | 445 (97) | 80 (99) | 12 (100) | ||
| Weighted Charlson/Deyo Index | 0 | 3252 (63) | 2552 (63) | 1602 (65) | 712 (58) | 238 (68) | 328 (62) | 22 (55) | 209 (62) | 97 (65) | 319 (69) | 46 (57) | 7 (58) | 0.001 |
| 1 | 797 (16) | 626 (15) | 378 (15) | 199 (16) | 49 (14) | 101 (19) | 8 (20) | 66 (20) | 27 (18) | 57 (12) | 10 (12) | 3 (25) | ||
| 2 | 394 (8) | 301 (7) | 185 (7) | 94 (8) | 22 (6) | 43 (8) | 5 (13) | 26 (8) | 12 (8) | 41 (9) | 8 (10) | 1 (8) | ||
| 3 | 695 (14) | 577 (14) | 305 (12) | 231 (19) | 41 (12) | 56 (11) | 5 (13) | 37 (11) | 14 (9) | 44 (10) | 17 (21) | 1 (8) | ||
| Specific comorbidities (nonexclusive) | Diabetes | 381 (7) | 315 (8) | 179 (7) | 112 (9) | 24 (7) | 32 (6) | 1 (3) | 26 (8) | 5 (3) | 19 (4) | 13 (16) | 2 (17) | 0.0002 |
| Alcohol abuse | 513 (10) | 378 (9) | 256 (10) | 97 (8) | 25 (7) | 55 (10) | 3 (8) | 37 (11) | 15 (10) | 73 (16) | 7 (9) | 0 (0) | < 0.0001 | |
| HBV coinfection | 46 (1) | 24 (1) | 9 (0) | 14 (1) | 1 (0) | 10 (2) | 0 (0) | 7 (2) | 3 (2) | 10 (2) | 1 (1) | 1 (8) | < 0.0001 | |
| HIV coinfection | 158 (3) | 127 (3) | 80 (3) | 38 (3) | 9 (3) | 16 (3) | 1 (3) | 10 (3) | 5 (3) | 11 (2) | 4 (5) | 0 (0) | 0.2881 | |
*
P-value for genotype based on χ2 test; subtype should be considered exploratory.
ALT indicates alanine aminotransferase; FIB4, Fibrosis-4; GHS, Geisinger Health System; GT, genotype; HFHS, Henry Ford Health System; KPHI, Kaiser-Permanente Hawai’I; KPNW, Kaiser-Permanente Northwest; ST, subtype.